Michot JM, et al. - In patients receiving antiprogrammed death-1 (anti-PD1) or antiprogrammed death ligand-1 (anti-PD-L1) treatments, all the lipase increases greater or equal to grade 2 were investigated in order to determine their biological and clinical significance. Based on the findings, it was concluded that the anti-PD-1 or anti-PD-L1 treatment can be continued in patients showing lipase increase but no symptoms and no radiographic abnormalities of the pancreas as increased lipase in the absence of these other parameters can be reasonably regarded as a not clinically significant event.